- Motley Fool
2 Reasons Why Eli Lilly's Stock Likely Hasn't Peaked
The stock may seem expensive right now, but that may not be the case in a few years.
- Barrons.com
Insulet Points Its Insulin Pump at the Big Diabetes Market: Type 2
Automated pumps are already used by about 40% of those with the autoimmune version of diabetes, known as Type-1.
- Zacks
Novo Nordisk (NVO) to Invest $4.1B in Clayton Facility Expansion
Novo Nordisk (NVO) plans to invest $4.1 billion in order to expand its Clayton facility with a second manufacturing plant, boosting capacity for injectable treatments and creating 1,000 new jobs.
